The clearance, granted via a Traditional 510(k) pathway, designates the device as substantially equivalent for its intended use, expanding Martech Medical's product offerings.
The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Martech Medical Products for its 25G Huber Needle. The decision, classifying the device as substantially equivalent, was formalized on September 18, 2026.
The 25G Huber Needle falls under product code PTI, regulated under 21 CFR 880.5570, which pertains to Intravascular Administration Sets. This device class is II, indicating a moderate risk profile that typically requires 510(k) premarket notification for new devices to demonstrate substantial equivalence to a legally marketed predicate device.
Regulatory Pathway and Device Classification
Martech Medical pursued clearance through the Traditional 510(k) pathway, a standard route for medical devices that are similar to existing products on the market. The FDA's determination of “substantially equivalent” means the agency found the 25G Huber Needle to be as safe and effective as a predicate device, without requiring a full premarket approval (PMA).
The advisory committee overseeing this classification was General Hospital, which typically reviews devices used in general medical and surgical practices. The clearance decision was based on a summary, the details of which are publicly available through the FDA's database.
Market Implications and Usage
Huber needles are specifically designed for accessing implanted ports, which are used for repeated intravenous administration of drugs, fluids, or blood products, particularly in patients undergoing long-term treatments like chemotherapy. The 25-gauge size indicates a fine needle, often favored for patient comfort or when smaller vessel access is required. While Martech Medical has secured regulatory clearance, specific details regarding the device's full feature set, market availability, or pricing have not yet been disclosed by the company.
